isis 681257
Nucleic acidexperimental
Clinical trial activity
4 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Mar 7, 2017 (NCT03070782)
Timeline
Indications
Mechanism of action
- Alpha-N-acetylgalactosaminide alpha-2,6-sialyltransferase IIIANTISENSE INHIBITOR
ST6GALNAC3 antisense inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- isis 681257
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03506854 | Phase 1 | Mar 20, 2018 | Akcea Therapeutics, Ionis Pharmaceuticals, Inc. |
| NCT03392051 | Phase 1 | Dec 28, 2017 | Akcea Therapeutics |
| NCT03426033 | Phase 1 | Dec 15, 2017 | Akcea Therapeutics |
| NCT03070782 | Phase 2 | Mar 7, 2017 | Akcea Therapeutics, Ionis Pharmaceuticals, Inc. |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Akcea Therapeutics | For profit | 4 | 3 | 2 | 2017 |
| Ionis Pharmaceuticals, Inc. | For profit | 2 | 1 | 2 | 2017 |
2 organizations
Page 1 / 1